UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000001958
Receipt number R000002386
Scientific Title Clinical safety and efficacy of combination of sustained-release morphine and transdermal fentanyl patch to the dyspnea in lung cancer patients
Date of disclosure of the study information 2009/06/01
Last modified on 2010/05/12 13:23:41

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical safety and efficacy of combination of sustained-release morphine and transdermal fentanyl patch to the dyspnea in lung cancer patients

Acronym

Clinical safety and efficacy of combination of sustained-release morphine and transdermal fentanyl patch to the dyspnea in lung cancer patients

Scientific Title

Clinical safety and efficacy of combination of sustained-release morphine and transdermal fentanyl patch to the dyspnea in lung cancer patients

Scientific Title:Acronym

Clinical safety and efficacy of combination of sustained-release morphine and transdermal fentanyl patch to the dyspnea in lung cancer patients

Region

Japan


Condition

Condition

lung cancer

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

We study to clarify whether the combination is effective and safe preparation of morphine sustainability, When you have a sense of cause breathing problems in lung cancer patients using the fentanyl skin patch drug for cancer pain,

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Improvement of dyspnea

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

administration of susteined-release morphine

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. diagnosed with lung cancer, announced that cancer patients
2. The patients age 20 or older
3. Patients are administered of transdermal fentanyl patch for cancer pains
4. Patients with dyspnea does not improve by including non-drug therapy,
oxygen.
5. A consent of patients is obtained in writing and fully explain the effects and side effects

Key exclusion criteria

1. Patients with severe cardiac dysfunction
2. Patients with severe renal or liver dysfunction
3. Patients with increased intracranial pressure
4. Patients with skin disorders such as atopic
5. Patients have a fever of more than 40 degree centigrade
6. Patients with impaired consciousness
7. Other than the orally drug (suppository drug and injection) is administered to patients by drug route of morphine

Target sample size

10


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yoshihiro Nishimura

Organization

Kobe University Graduate School of Medicine

Division name

Division of Respiratory Medicine, Department of Internal Medicine

Zip code


Address

, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Japan

TEL

078-382-5111

Email



Public contact

Name of contact person

1st name
Middle name
Last name Akihiro Sakashita

Organization

Kobe University Graduate School of Medicine

Division name

Division of Respiratory Medicine, Department of Internal Medicine

Zip code


Address


TEL

078-382-5846

Homepage URL


Email

meidai@med.kobe-u.ac.jp


Sponsor or person

Institute

Kobe University Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

nothing

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2009 Year 06 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2009 Year 05 Month 01 Day

Date of IRB


Anticipated trial start date

2009 Year 06 Month 01 Day

Last follow-up date

2010 Year 05 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2009 Year 05 Month 11 Day

Last modified on

2010 Year 05 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002386


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name